Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Advanced melanoma treatments have evolved with targeted therapies and immunotherapies.
• These novel treatments, including BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors (anti-CTLA4, anti-PD1), are increasingly used.
• Adverse cutaneous events are common side effects associated with these advanced melanoma therapies.

Purpose of the Study:

• To review the spectrum of cutaneous adverse events associated with advanced melanoma treatments.
• To discuss the management strategies for these treatment-related skin toxicities.
• To highlight the importance of early detection for patient outcomes.

Main Methods:

• Literature review of cutaneous adverse events from targeted therapies and immunotherapies for advanced melanoma.
• Synthesis of information on the incidence, clinical presentation, and management of various skin toxicities.
• Analysis of the impact of adverse events on treatment continuation and quality of life.

Main Results:

• Cutaneous adverse events range from cosmetic changes (e.g., curly hair) to severe conditions (e.g., cutaneous squamous cell carcinoma, toxic epidermal necrolysis).
• BRAF inhibitors, MEK inhibitors, and immunotherapies each present distinct patterns of skin toxicity.
• Effective management can mitigate side effects, allowing patients to continue anti-tumour therapy.

Conclusions:

• Cutaneous adverse events are a significant consideration in the management of advanced melanoma.
• Prompt identification and appropriate intervention for skin toxicities are crucial for patient well-being.
• Managing these adverse events optimizes treatment efficacy and enhances the quality of life for melanoma patients.